Sunday 18 October 2026
Export NXL’s income statement to Excel — free account
Nexalin Technology, Inc.
NXL Healthcare Medical Devices
Nexalin Technology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $301,600.00, up 78.8% from fiscal 2024. In the quarter to June 2026, revenue fell 82.7%, EPS fell 10.0% and free cash flow fell 97.2%, each against the same quarter a year earlier.
2.35
0.10
−4.08%
Follow NXL
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
2 | 5 | 5 | 5 |
| (178.46%) | (221.50%) | (319.69%) | (240.25%) | ||
| (167.17%) | (185.64%) | (252.65%) | (187.89%) | ||
ROIC |
(1,331.05%) | (21,146.42%) | (2,987.77%) | (1,108.82%) | |
Return on Tangible Assets |
(194.60%) | (240.98%) | (329.66%) | (2,141.72%) | |
Average Days of Receivables |
18.38 | 98.75 | 56.95 | 88.90 | |
Free Cash Flow per Share |
(8.48) | (9.26) | (8.37) | (9.00) | |
Free Cash Flow |
(5.02) | (5.05) | (5.52) | (6.34) | |
Capital Expenditures |
(0.08) | (0.10) | (0.28) | (0.21) | |
| Other line items | |||||
Cash ROIC |
(55.08%) | (67.65%) | (98.70%) | (251.06%) | |
Accounts Receivable Turnover |
13.58 | 6.38 | 9.59 | 3.85 | |
Accounts Payable Turnover |
0.41 | 0.31 | 0.28 | 0.13 | |
Inventory Turnover |
0.30 | 0.40 | 0.28 | 0.15 | |
Average Days of Payables |
515.43 | 1,456.43 | 1,239.53 | 2,912.70 | |
Days of Inventory on Hand |
1,223.28 | 782.99 | 1,323.59 | 2,840.92 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,017.08% | 359.25% | 371.41% | 627.21% | |
Selling, General and Administrative Expense of Revenue |
4,694.90% | 2,502.52% | 2,794.59% | 3,660.59% | |
Share Based Compensation of Revenue |
2,449.59% | 1,035.58% | 1,075.87% | 1,289.78% | |
Interest Coverage |
(9,836.78) | 1,023.28 | 913.94 | 656.55 | |
Operating CF/Net income |
0.57 | 0.60 | 0.63 | 0.68 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.61 | 1.07 | |
Capex/Depreciation |
(4.01) | (4.51) | (10.09) | (4.59) | |
Revenue per Share |
0.26 | 0.55 | 0.42 | 0.31 | |
Operating CF per Share |
(8.34) | (9.08) | (7.95) | (8.70) | |
Capex per Share |
(0.13) | (0.18) | (0.42) | (0.30) | |
Capex to Sales |
0.51 | 0.32 | 1.01 | 0.96 |
Columns are period end dates · fundamentals updated 2 Oct 2026